series-c-plus
Stage
2021
Founded
2
Investors
About
InventisBio is a clinical-stage biotechnology company headquartered in Shanghai, China, developing small-molecule drugs for oncology, autoimmune diseases and metabolic disorders. The company has two approved drugs and multiple clinical candidates, including TYK2 inhibitor D-2570 and oral SERD taragarestrant (D-0502), with core programs advancing through Phase III registration trials.
Explore InventisBio Co., Ltd.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.